Artelo Biosciences (ARTL) Accounts Payables (2015 - 2025)
Artelo Biosciences (ARTL) posted quarterly Accounts Payables of $3.0 million for Q4 2025, up 81.09% year-over-year from $1.7 million in Q4 2024, and down 21.54% quarter-over-quarter from $3.9 million in Q3 2025.
Artelo Biosciences (ARTL) Accounts Payables (2015 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Accounts Payables for 11 consecutive years, with $3.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables rose 81.09% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (up 81.09% YoY), while the FY2025 annual figure was $3.0 million, up 81.09% from the prior year.
- Accounts Payables declined to $3.0 million in Q4 2025 per ARTL's latest filing, from $3.9 million in the prior quarter.
- Across five years, Accounts Payables topped out at $4.8 million in Q2 2025 and bottomed at $411000.0 in Q3 2022.
- Historically, Accounts Payables has averaged $1.4 million across 5 years, with a median of $820000.0 in 2022.
- Annual changes were most pronounced in 2024 — Accounts Payables decreased 25.36% — and 2025, when it surged 516.91%.
- Artelo Biosciences' Accounts Payables stood at $590000.0 in 2021, then jumped by 53.39% to $905000.0 in 2022, then soared by 36.8% to $1.2 million in 2023, then jumped by 35.38% to $1.7 million in 2024, then jumped by 81.09% to $3.0 million in 2025.
- Business Quant data shows ARTL's Accounts Payables at $3.0 million in Q4 2025, $3.9 million in Q3 2025, and $4.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | 3.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.04 Mn |
| Sep 30, 2025 | 3.87 Mn |
| Jun 30, 2025 | 4.84 Mn |
| Mar 31, 2025 | 2.51 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Sep 30, 2024 | 627,000.00 |
| Jun 30, 2024 | 863,000.00 |
| Mar 31, 2024 | 607,000.00 |
| Dec 31, 2023 | 1.24 Mn |
| Sep 30, 2023 | 840,000.00 |
| Jun 30, 2023 | 523,000.00 |
| Mar 31, 2023 | 701,000.00 |
| Dec 31, 2022 | 905,000.00 |
| Sep 30, 2022 | 411,000.00 |
| Jun 30, 2022 | 432,000.00 |
| Mar 31, 2022 | 800,000.00 |
| Nov 30, 2021 | 590,000.00 |
| Aug 31, 2021 | 471,000.00 |
| Aug 31, 2020 | 489,000.00 |
| Aug 31, 2019 | 348,863.00 |